Advertisement

Combination Therapy

  • Mio Nakamura
  • Caleb Jeon
  • John Koo
Chapter
Part of the Updates in Clinical Dermatology book series (UCD)

Abstract

Psoriasis is a chronic inflammatory skin disease with a remitting and relapsing course. Long-term remission can be difficult to achieve regardless of severity of psoriasis. Using two or more therapies with varying mechanisms of action and safety profiles is often necessary to maintain adequate disease control while minimizing toxicity of treatments. Choosing a combination regimen that maximizes safety and efficacy, while at the same time considers patient usability and compliance, can be difficult. Presently, numerous treatment options are available for the treatment of psoriasis including topical agents, phototherapy, oral systemic agents, and biologics, with many more therapeutic agents in the pipeline. With the increasing number of available therapies, there are many opportunities to combine various therapies. It is crucial for clinicians to carefully consider the fine balance between safety and efficacy when combining various therapeutic agents and utilize strategies such as rotational therapy and sequential therapy when appropriate. This chapter will review various combination therapy strategies for the treatment of psoriasis.

Keywords

Psoriasis Combination therapy Rotational therapy Sequential therapy 

References

  1. 1.
    Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol. 1993;28(3):454–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol. 1999;41(3 Pt 2):S25–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Emer J, Lebwohl MG. Combination, rotational, and sequential therapies. In: Koo JYM, Levin EC, Leon AWJJ, Gottlieb AB, editors. Moderate to severe psoriasis. Boca Raton: CRC Press; 2015. p. 121–38.Google Scholar
  4. 4.
    Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50(3):416–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Menter MA, See JA, Amend WJ, et al. Proceedings of the psoriasis combination and rotation therapy conference, Deer Valley, Utah, Oct. 7–9, 1994. J Am Acad Dermatol. 1996;34(2 Pt 1):315–21.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Koo JYM. New developments in topical sequential therapy for psoriasis. Skin Therapy Lett. 2005;10(9):1–4.PubMedGoogle Scholar
  7. 7.
    Horn EJ, Domm S, Katz HI, et al. Topical corticosteroids in psoriasis: strategies for improving safety. J Eur Acad Dermatol Venereol. 2010;24(2):119–24.CrossRefPubMedGoogle Scholar
  8. 8.
    Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol. 1997;37(3 Pt 2):S55–8.PubMedGoogle Scholar
  9. 9.
    Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35(2 Pt 1):268–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39(3):447–50.CrossRefPubMedGoogle Scholar
  11. 11.
    Austad J, Bjerke JR, Gjertsen BT, et al. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 1998;11(1):19–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Bhutani T, Zitelli KB, Koo J. Yin-yang strategy: proposing a new, effective, repeatable, sequential therapy for psoriasis. J Drugs Dermatol. 2011;10(8):831–4.PubMedGoogle Scholar
  13. 13.
    Menter A, Sofen H, Smith S, et al. An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis. Cutis. 2011;88(1):46–51.PubMedGoogle Scholar
  14. 14.
    Brodell RT, Bruce S, Hudson CP, et al. A multi-center, open-label study to evaluate the safety and efficacy of a sequential treatment regimen of clobetasol propionate 0.05% spray followed by Calcitriol 3 mg/g ointment in the management of plaque psoriasis. J Drugs Dermatol. 2011;10(2):158–64.PubMedGoogle Scholar
  15. 15.
    Hudson CP, Kempers S, Menter A, et al. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis. Cutis. 2011;88(4):201–7.PubMedGoogle Scholar
  16. 16.
    Koo J, Blum RR, Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol. 2006;55(4):637–41.CrossRefPubMedGoogle Scholar
  17. 17.
    Singh S, Reddy DC, Pandey SS. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. J Am Acad Dermatol. 2000;43(1 Pt 1):61–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol. 2001;40(1):64–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther. 2000;22(10):1225–38.CrossRefPubMedGoogle Scholar
  20. 20.
    Tanghetti EA. Tazarotene Stable Plaque Psoriasis Trial Study Group. An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/− corticosteroid. Cutis. 2000;66(6 Suppl):12–8.PubMedGoogle Scholar
  21. 21.
    Dubertret L, Lahfa M, Altmeyer P, Prens EP, Matranga A Alternating evening applications of tazarotene 0.1% gel and corticosteroid cream in the treatment of plaque psoriasis, Poster presented at the 56th annual meeting of the American Academy of Dermatology. Orlando, FL, 27 February–4 March 1998.Google Scholar
  22. 22.
    Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39(4 Pt 1):590–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Lebwohl M, Poulin Y. Tazarotene in combination with topical corticosteroids. J Am Acad Dermatol. 1998;39(4 Pt 2):S139–43.CrossRefPubMedGoogle Scholar
  24. 24.
    Kaidbey K, Kopper SC, Sefton J, Gibson JR A pilot study to determine the effect of tazarotene 0.1% gel on steroid-induced epidermal atrophy. Poster presented at the 58th annual meeting of the American Academy of Dermatology. San Francisco, CA, 10–15 March 2000.Google Scholar
  25. 25.
    Koo J, Behnam SE, Behnam SM. The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis. Expert Opin Pharmacother. 2003;4(12):2347–54.CrossRefPubMedGoogle Scholar
  26. 26.
    Hecker D, Worsley J, Yueh G, et al. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol. 2000;42:1008–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol. 2002;46(6):907–13.CrossRefPubMedGoogle Scholar
  28. 28.
    Meola T Jr, Soter NA, Lim HW. Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation? A review of the literature. Arch Dermatol. 1991;127(11):1708–13.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS. Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol. 1989;20:748–54.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Petrozzi JW. Topical steroids and UV radiation in psoriasis. Arch Dermatol. 1983;119:207–10.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Horwitz SN, Johnson RA, Sefton J, Frost P. Addition of a topically applied corticosteroid to a modified Goeckerman regimen for treatment of psoriasis: effect on duration of remission. J Am Acad Dermatol. 1985;13:784–91.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Koo J. Calcipotriol/calcipotriene (Dovonex/Daivonex) in combination with phototherapy: a review. J Am Acad Dermatol. 1997;37(3 Pt 2):S59–61.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Kerscher M, Volkenandt M, Plewig G, Lehmann P. Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB. Lancet. 1993;342(8876):923.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Kokelj F, Lavaroni G, Guadagnini A. UVB versus UVB plus calcipotriol (MC 903) therapy for psoriasis vulgaris. Acta Derm Venereol. 1995;75(5):386–7.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Hecker D, Lebwohl M. Topical calcipotriene in combination with UVB phototherapy for psoriasis. Int J Dermatol. 1997;36(4):302–3.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Molin L. Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology. 1999;198(4):375–81.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ring J, Kowalzick L, Christophers E, et al. Calcitriol 3 microg g−1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol. 2001;144(3):495–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Rim JH, Choe YB, Youn JI. Positive effect of using calcipotriol ointment with narrow-band ultraviolet B phototherapy in psoriatic patients. Photodermatol Photoimmunol Photomed. 2002;18(3):131–4.CrossRefPubMedGoogle Scholar
  39. 39.
    Ozkan I, Köse O, Ozmen I, Arca E. Efficacy and safety of non-laser, targeted UVB phototherapy alone and in combination with psoralen gel or calcipotriol ointment in the treatment of localized, chronic, plaque-type psoriasis. Int J Dermatol. 2012;51(5):609–13.CrossRefPubMedGoogle Scholar
  40. 40.
    Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week. J Dermatol. 2013;40(6):424–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Lebwohl M, Hecker D, Martinez J, Sapadin A, Patel B. Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol. 1997;37(1):93–5.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Kragballe K. Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. Dermatologica. 1990;181(3):211–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Brands S, Brakman M, Bos JD, de Rie MA. No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis. J Am Acad Dermatol. 1999;41(6):991–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Koo JY. Tazarotene in combination with phototherapy. J Am Acad Dermatol. 1998;39(4 Pt 2):S144–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Behrens S, Grundmann-Kollmann M, Schiener R, Peter RU, Kerscher M. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol. 2000;42(3):493–5.CrossRefPubMedGoogle Scholar
  46. 46.
    Lowe NJ. Optimizing therapy: tazarotene in combination with phototherapy. Br J Dermatol. 1999;140(Suppl 54):8–11.CrossRefPubMedGoogle Scholar
  47. 47.
    Koo JY, Lowe NJ, Lew-Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol. 2000;43(5 Pt 1):821–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Hecker D, Worsley J, Yueh G, Kuroda K, Lebwohl M. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol. 1999;41(6):927–30.CrossRefPubMedGoogle Scholar
  49. 49.
    Lee E, Koo J. Modern modified ‘ultra’ Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. J Dermatolog Treat. 2005;16(2):102–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Lowe NJ, Wortzman MS, Breeding J, Koudsi H, Taylor L. Coal tar phototherapy for psoriasis reevaluated: erythemogenic versus suberythemogenic ultraviolet with a tar extract in oil and crude coal tar. J Am Acad Dermatol. 1983;8(6):781–9.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Menter A, Cram DL. The Goeckerman regimen in two psoriasis day care centers. J Am Acad Dermatol. 1983;9(1):59–65.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Gupta R, Debbaneh M, Butler D, et al. The Goeckerman regimen for the treatment of moderate to severe psoriasis. J Vis Exp. 2013;77:e50509. https://doi.org/10.3791/50509.CrossRefGoogle Scholar
  53. 53.
    Bagel J. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone. J Drugs Dermatol. 2009;8(4):351–7.PubMedGoogle Scholar
  54. 54.
    Lebwohl M, Martinez J, Weber P, DeLuca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol. 1995;32(3):469–71.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Boer J, Smeenk G. Effect of short-contact anthralin therapy on ultraviolet B irradiation of psoriasis. J Am Acad Dermatol. 1986;15(2 Pt 1):198–204.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Lebwohl M, Berman B, France DS. Addition of short-contact anthralin therapy to an ultraviolet B phototherapy regimen: assessment of efficacy. J Am Acad Dermatol. 1985;13:780–4.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Morison WL, Parrish JA, Fitzpatrick TB. Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis. Br J Dermatol. 1978;98(2):125–32.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Schmoll M, Henseler T, Christophers E. Evaluation of PUVA, topical corticosteroids and the combination of both in the treatment of psoriasis. Br J Dermatol. 1978;99(6):693–702.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Hanke CW, Steck WD, Roenigk HH. Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate. Arch Dermatol. 1979;115(9):1074–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Gould PW, Wilson L. Psoriasis treated with clobetasol propionate and photochemotherapy. Br J Dermatol. 1978;98(2):133–6.CrossRefPubMedGoogle Scholar
  61. 61.
    Speight EL, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol. 1994;130(1):79–82.CrossRefPubMedGoogle Scholar
  62. 62.
    Frappaz A, Thivolet J. Calcipotriol in combination with PUVA: a randomized, double-blind, placebo study in severe psoriasis. Eur J Dermatol. 1993;3:351–4.Google Scholar
  63. 63.
    Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. Arch Dermatol. 2000;136(12):1536–43.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Behrens S, Grundmann-Kollmann M, Peter RU, Kerscher M. Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid. Br J Dermatol. 1999;141(1):177.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Wong JW, Nguyen TV, Bhutani T, Koo JY. Treatment of psoriasis and long-term maintenance using 308 nm excimer laser, clobetasol spray, and calcitriol ointment: a case series. J Drugs Dermatol. 2012 Aug;11(8):994–6.PubMedGoogle Scholar
  66. 66.
    Levin E, Debbaneh M, Malakouti M. Supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis: interim results of an open label pilot study. J Dermatolog Treat. 2015;26(1):16–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Levin E, Nguyen CM, Danesh MJ, Beroukhim K, Leon A, Koo J. An open label pilot study of supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis. J Dermatolog Treat. 2016;27(3):210–3.CrossRefPubMedGoogle Scholar
  68. 68.
    Dong J, He Y, Zhang X, et al. Clinical efficacy of flumetasone/salicylic acid ointment combined with 308-nm excimer laser for treatment of psoriasis vulgaris. Photodermatol Photoimmunol Photomed. 2012;28(3):133–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Rogalski C, Grunewald S, Schetschorke M, et al. Treatment of plaque-type psoriasis with the 308 nm excimer laser in combination with dithranol or calcipotriol. Int J Hyperth. 2012;28(2):184–90.CrossRefGoogle Scholar
  70. 70.
    Polano MK, van der Rhee HJ, van der Schroeff JG. A three-year follow-up study of psoriasis patients treated with low dosages of etretinate orally and corticosteroids topically. Acta Derm Venereol. 1982;62(4):361–4.PubMedGoogle Scholar
  71. 71.
    van de Kerkhof PC, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol. 1998;138(1):84–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Rim JH, Park JY, Choe YB, Youn JI. The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy. Am J Clin Dermatol. 2003;4(7):507–10.CrossRefPubMedGoogle Scholar
  73. 73.
    Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol. 1994;31(1):68–74.CrossRefPubMedGoogle Scholar
  74. 74.
    Katz HI. Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists. J Am Acad Dermatol. 1997;37(3 Pt 2):S62–8.PubMedGoogle Scholar
  75. 75.
    de Jong EM, Mørk NJ, Seijger MM, De La Brassine M, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol. 2003;148(2):318–25.CrossRefPubMedGoogle Scholar
  76. 76.
    Lebwohl MG, Kircik L, Callis Duffin K, et al. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2013;69(3):385–92.CrossRefPubMedGoogle Scholar
  77. 77.
    Feldman SR, Koo JY, Johnson LA, Preston NJ. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis. 2009;84(4 Suppl):25–32.PubMedGoogle Scholar
  78. 78.
    Campione E, Mazzotta A, Paternò EJ, Diluvio L, Prinz JC, Chimenti S. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients. Acta Derm Venereol. 2009;89(3):288–91.CrossRefPubMedGoogle Scholar
  79. 79.
    Kircik LH. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial. J Drugs Dermatol. 2011;10(8):878–82.PubMedGoogle Scholar
  80. 80.
    D T, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163(2):402–11.CrossRefGoogle Scholar
  81. 81.
    Momtaz-T K, Parrish JA. Combination of psoralens and ultraviolet A and ultraviolet B in the treatment of psoriasis vulgaris: a bilateral comparison study. J Am Acad Dermatol. 1984;10(3):481–6.CrossRefPubMedGoogle Scholar
  82. 82.
    Calzavara-Pinton P. Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination. J Am Acad Dermatol. 1998;38:687–90.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Morison WL. Combination of methoxsalen and ultraviolet B (UVB) versus UVB radiation alone in treatment of psoriasis: a bilateral comparison study. Photodermatol Photoimmunol Photomed. 1995;11(1):6–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Park YK, Kim HJ, Koh YJ. Combination of photochemotherapy (PUVA) and ultraviolet B (UVB) in the treatment of psoriasis vulgaris. J Dermatol. 1988;15(1):68–71.CrossRefPubMedGoogle Scholar
  85. 85.
    Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol. 1999;41(3 Pt 2):S22–4.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Bhutani T, Koo J. A review of the chemopreventative effects of oral retinoids for internal neoplasms. J Drugs Dermatol. 2011;10(11):1292–8.PubMedGoogle Scholar
  87. 87.
    Wang E, Sasaki J, Nakamura M, et al. Cuaneous carcinogenic risk of phototherapy: an updated comprehensive review. J Psoriasis Psoriatic Arth. 2015;1(1):44–51.CrossRefGoogle Scholar
  88. 88.
    Busse K, Koo J. Introducing the delayed retinoid burn: a case report and discussion of this potential risk of retinoid-phototherapy combination management. J Am Acad Dermatol. 2011 May;64(5):1011–2.CrossRefPubMedGoogle Scholar
  89. 89.
    Ruzicka T, Sommerburg C, Braun-Falco O, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol. 1990;126(4):482–6.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol. 1989;120(5):665–70.CrossRefPubMedGoogle Scholar
  91. 91.
    Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991;24(4):591–4.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Saurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica. 1988;177(4):218–24.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Lauharanta J, Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol. 1989;121(1):107–12.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Tanew A, Guggenbichler A, Hönigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991;25(4):682–4.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Neoral [package insert]. East Hanover: Novartis; 2015.Google Scholar
  96. 96.
    Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA. Combined methotrexate--ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982;7(6):758–62.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982;6(1):46–51.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–99.CrossRefPubMedGoogle Scholar
  99. 99.
    AbuHilal M, Walsh S, Shear N. Use of Apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutan Med Surg. 2016;20(4):313–6.CrossRefPubMedGoogle Scholar
  100. 100.
    De Simone C, D’Agostino M, Capizzi R, et al. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. Eur J Dermatol. 2011;21(4):568–72.PubMedGoogle Scholar
  101. 101.
    Kircik L, Bagel J, Korman N, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol. 2008;7(3):245–53.PubMedPubMedCentralGoogle Scholar
  102. 102.
    Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol. 2009;160(1):186–9.CrossRefPubMedGoogle Scholar
  103. 103.
    Lynde CW, Gupta AK, Guenther L, et al. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat. 2012;23(4):261–7.CrossRefPubMedGoogle Scholar
  104. 104.
    Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol. 2011;164(6):1383–6.CrossRefPubMedGoogle Scholar
  105. 105.
    Calzavara-Pinton PG, Sala R, Arisi M, et al. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis. Br J Dermatol. 2013;169(1):130–6.CrossRefPubMedGoogle Scholar
  106. 106.
    Park KK, Swan J, Koo J. Effective treatment of etanercept and phototherapy-resistant psoriasis using the excimer laser. Dermatol Online J. 2012;18(3):2.PubMedGoogle Scholar
  107. 107.
    Park KK, Wu JJ, Koo J. A randomized, ‘head-to-head’ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol. 2013;27(7):899–906.CrossRefPubMedGoogle Scholar
  108. 108.
    Strober B, Gottlieb A, Leonardi C, et al. Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. J Am Acad Dermatol. 2006;54(3 Suppl):AB220.Google Scholar
  109. 109.
    Bagel J. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis. J Drugs Dermatol. 2011;10(4):366–71.PubMedGoogle Scholar
  110. 110.
    Wolf P, Hofer A, Weger W, et al. 311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed. 2011;27(4):86–9.CrossRefGoogle Scholar
  111. 111.
    Wolf P, Weger W, Legat FJ, et al. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol. 2012;166(1):147–53.CrossRefPubMedGoogle Scholar
  112. 112.
    Lowenthal KE, Horn PJ, Kalb RE. Concurrent use of methotrexate and acitretin revisited. J Dermatolog Treat. 2008;19(1):22–6.CrossRefPubMedGoogle Scholar
  113. 113.
    Vanderveen EE, Ellis CN, Campbell JP, Case PC, Voorhees JJ. Methotrexate and etretinate as concurrent therapies in severe psoriasis. Arch Dermatol. 1982;118(9):660–2.CrossRefPubMedGoogle Scholar
  114. 114.
    Rosenbaum MM, Roenigk HH. Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate. J Am Acad Dermatol. 1984;10(2 Pt 2):357–61.CrossRefPubMedGoogle Scholar
  115. 115.
    Tuyp E, MacKie RM. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acad Dermatol. 1986;14(1):70–3.CrossRefPubMedGoogle Scholar
  116. 116.
    Soriatane [package insert]. Research Triangle Park; Stiefel: 2015.Google Scholar
  117. 117.
    Clark CM, Kirby B, Morris AD, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999;141(2):279–82.CrossRefPubMedGoogle Scholar
  118. 118.
    Aydin F, Canturk T, Senturk N, Turanli AY. Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol. 2006;31(4):520–4.CrossRefPubMedGoogle Scholar
  119. 119.
    Ellis CN, Reiter KL, Bandekar RR, Fendrick AM. Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate. J Am Acad Dermatol. 2002;46(2):242–50.CrossRefPubMedGoogle Scholar
  120. 120.
    Sasaki J, Zhu TH, Austin A, Nakamura M, Koo J. Apremilast and cyclosporine combination therapy for a patient with both psoriasis and psoriatic arthritis: a case report. J Psoriasis Psoriatic Arth. 2016;1(2):70–2.CrossRefGoogle Scholar
  121. 121.
    Colao R, Yanofsky VR, Lebhowl MG. Successful treatment of palmoplantar psoriasis using combination acitretin and apremilast: a case report. J Psoriasis Psoriatic Arth. 2016;1(2):66–9.CrossRefGoogle Scholar
  122. 122.
    Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. 2008;158(6):1345–9.CrossRefPubMedGoogle Scholar
  123. 123.
    Philipp S, Wilsmann-Theis D, Weyergraf A, et al. Combination of adalimumab with traditional systemic antipsoriatic drugs—a report of 39 cases. J Dtsch Dermatol Ges. 2012;10(11):821–37.PubMedGoogle Scholar
  124. 124.
    Smith EC, Riddle C, Menter MA, Lebwohl M. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol. 2008;47(5):514–8.CrossRefPubMedGoogle Scholar
  125. 125.
    Conley J, Nanton J, Dhawan S, et al. Novel combination regimens: biologics and acitretin for the treatment of psoriasis—a case series. J Dermatol Treat. 2006;17:86–9.CrossRefGoogle Scholar
  126. 126.
    Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151(4):432–8.CrossRefPubMedGoogle Scholar
  127. 127.
    Lee EJ, Shin MK, Kim NI. A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol. 2010;22(2):138–42.CrossRefPubMedPubMedCentralGoogle Scholar
  128. 128.
    D'Angelo S, Cutro MS, Lubrano E, et al. Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69(5):934–5.CrossRefPubMedGoogle Scholar
  129. 129.
    Yamauchi PS, Lowe NJ. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S135–8.CrossRefPubMedGoogle Scholar
  130. 130.
    Gattu S, Wu J, Koo J. Can adalimumab make a smooth and easy transition from cyclosporine a reality? A case series of successful transitions. Psoriasis Forum. 2009;15(2):33–5.CrossRefGoogle Scholar
  131. 131.
    Ortiz A, Yamauchi PS. A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents. Skinmed. 2006;5:285–8.CrossRefPubMedGoogle Scholar
  132. 132.
    Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167(3):649–57.CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Zachariae C, Mørk NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88(5):495–501.CrossRefPubMedGoogle Scholar
  134. 134.
    Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol. 2008;159(2):460–3.CrossRefPubMedGoogle Scholar
  135. 135.
    Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol. 2002;146(1):118–21.CrossRefPubMedGoogle Scholar
  136. 136.
    Dalaker M, Bonesrønning JH. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol. 2009;23(3):277–82.CrossRefPubMedGoogle Scholar
  137. 137.
    van den Reek JM, van Lümig PP, Kievit W, et al. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J Dermatolog Treat. 2013;24(5):361–8.CrossRefPubMedGoogle Scholar
  138. 138.
    Strober BE, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. J Drugs Dermatol. 2004;3(3):270–2.PubMedGoogle Scholar
  139. 139.
    De Groot M, Teunissen MBM, Picavet DI, et al. Adalimumab in combination with methotrexate more effectively reduces the numbers of different inflammatory cell types in lesional psoriatic skin than does single treatment with adalimumab or methotrexate. Br J Dermatol. 2008;159:1401.Google Scholar
  140. 140.
    Yamauchi PS, Lowe NJ. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis. Int J Dermatol. 2008;47(2):202–4.CrossRefPubMedGoogle Scholar
  141. 141.
    Farhangian ME, Feldman SR. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate. Am J Clin Dermatol. 2015;16(4):285–94.CrossRefPubMedGoogle Scholar
  142. 142.
    Heinecke GM, Luber AJ, Levitt JO, Lebwohl MG. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. J Drugs Dermatol. 2013 Oct;12(10):1098–102.PubMedGoogle Scholar
  143. 143.
    Danesh MJ, Beroukhim K, Nguyen C, Levin E, Koo J. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis. Dermatol Online J. 2015;21(6)Google Scholar
  144. 144.
    Rothstein BE, McQuade B, Greb JE, Goldminz AM, Gottlieb AB. Apremilast and secukinumab combined therapy in a patient with recalcitrant plaque psoriasis. J Drugs Dermatol. 2016;15(5):648–9. pii: 13030/qt5gf406zsGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Dermatology, Psoriasis and Skin Treatment CenterUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Department of Dermatology, UCSF Psoriasis CenterUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations